Wilson Sonsini Goodrich & Rosati advised New Enterprise Associates (NEA) and Versant Ventures on the deal.858 Therapeutics announced the completion of a $60 million Series A…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
